熱門資訊> 正文
FDA授予BioAlta的ozuriiftamab vedotin快速通道地位
2024-07-23 23:29
- BioAlta (NASDAQ:BCAB) said the FDA has granted Fast Track Designation to its antibody drug conjugate ozuriftamab vedotin in the treatment of certain patients with squamous cell carcinoma of the head and neck, or SCCHN.
- The agency granted the designation for the treatment of patients with recurrent or metastatic SCCHN with disease progression on or after platinum-based chemotherapy and anti-PD-1/L1 antibody therapy, according to a statement.
- BioAtla (BCAB) added it was on track to meet with the agency for guidance on a potentially registrational study in the second half of 2024.
More on BioAtla
- BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript
- BioAtla: A Buried ADC Concern Gets Some New Life In 2024
- Seeking Alpha’s Quant Rating on BioAtla
- Historical earnings data for BioAtla
- Financial information for BioAtla
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
